Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Although cost-related asthma treatment nonadherence has declined in the US, nearly 1 in 6 patients are still nonadherent due to cost concerns.

Faster post-COVID-19 recovery is observed after infection with the Omicron vs earlier variants, regardless of vaccination status.

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.

The United States Food and Drug Administration has authorized the marketing of 20 ZYN nicotine pouch products.